IN THE CLAIMS

Please cancel claims 1-62 without prejudice or disclaimer.

REMARKS

The instant Preliminary Amendment is responsive to the Notice To File Corrected Application Papers dated 04/18/2002. A substitute specification is enclosed which has proper margins. Furthermore, a substitute paper Sequence Listing is enclosed.

Claims 1-62 have been canceled. Therefore, claims 63-65 are pending.

SEQUENCE STATEMENT UNDER 37 CFR §§ 1.821 - 1.825

The substitute paper Sequence Listing submitted herewith is identical to the paper and computer readable form (CRF) Sequence Listing in parent Application No. 09/328,188, filed June 8, 1999 (now U.S. Pat. No. 6,326,205. Pursuant to 37 CFR § 1.821(e), please use the CRF sequence listing from parent Application No. 09/328,188 for purposes of examination of the instant application.

No new matter has been added. Applicants therefore respectfully request favorable examination and issuance of the pending claims.

Respectfully submitted,

Attorney for Applicants

Registration No. 38,241

J. Timothy Meigs

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

Telephone: 301-258-4715

Date: May 8, 2002